Sector News

Sunshine Act payment data leaves out newly influential prescribers

July 8, 2015
Life sciences
The Physician Payments Sunshine Act was meant to shine a light on pharma’s payments to doctors, boosting transparency and potentially reducing unsavory business practices. But the act leaves out a big chunk of prescribers: nurse practitioners and physician assistants (PAs).
 
As NPR reports, nurse practitioners and PAs play an increasingly large role in healthcare, taking on many of the same tasks as doctors. PAs and nurses wrote about 10% of the nearly 1.4 billion prescriptions in Medicare’s prescription drug program in 2013, according to a ProPublica analysis cited by NPR. The two groups wrote 15% of all scripts nationwide during the first 5 months of the same year, an IMS Health study notes.
 
While pharma’s relationships with doctors have historically drawn the most attention, nurses’ interactions with the industry have “as much relevance,” Dr. Walid Gellad, co-director of the University of Pittsburgh’s Center for Pharmaceutical Policy and Prescribing, told the news outlet. “If the purpose of the act is to shine a light on the relationship between industry and the healthcare sector, then you’ve left out an important component of that sector,” he said.
 
When the Sunshine Act was drafted, nursing groups weren’t covered by the law and thus weren’t a part of policy discussions, Allan Coukell, senior director for health programs at the Pew Charitable Trusts, told NPR. But just because that’s how the system worked in the past doesn’t mean it should continue in the same vein, he added.
 
“(T)o the extent that a lot of prescribing now is done by health professionals who aren’t physicians, and a lot of marketing is directed at them, they ideally should also be part of the disclosure,” Coukell said (as quoted by NPR).
 
Meanwhile, the industry has slowly begun to change its tune when it comes to interactions with healthcare providers. In 2013, GlaxoSmithKline CEO Andrew Witty pledged to end doctor payments by 2016 to give the company’s image a much-needed boost. While the company has yet to make big moves in that department, GSK plans to roll out a new suite of services by 2016 to replace paid speakers, loosening its ties with doctors. “We expect overall payments to continue decreasing as we continue to implement our new approach to working with healthcare professionals,” company spokeswoman Sarah Alspach told Bloomberg last month.
 
By Emily Wasserman
 

comments closed

Related News

April 20, 2024

CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines

Life sciences

CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.

April 20, 2024

FUJIFILM plans $1.2 billion investment in major US manufacturing facility

Life sciences

FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.

April 20, 2024

Sanofi cuts staff in Belgium as early-stage research dwindles

Life sciences

Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.

How can we help you?

We're easy to reach